Inovio Pharmaceuticals Inc expected to post a loss of 100 cents a share - Earnings Preview

Inovio Pharmaceuticals

10/05/2024 21:37

* Inovio Pharmaceuticals Inc  INO.OQ   INO.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 13
for the period ending March 31 2024
    * The San Diego California-based  company is expected to
report a
32.3% increase in revenue to $150.8 thousand from $114 thousand
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Inovio Pharmaceuticals
Inc is
for a loss of 100 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Inovio
Pharmaceuticals Inc is $14.50​, above​ its last closing price
of $11.18. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -1.42       -1.27      -1.12     Beat    11.6
 Sep. 30 0001  -1.50       -1.52      -1.56     Missed  -2.6
 Jun. 30 2023  -1.81       -1.74      -1.56     Beat    10.3​
 Mar. 31 2023  -1.76       -1.74      -1.92     Missed  -10.3
 ​​Dec.        -2.01       -2.02      -2.52     Missed  -25
 31 2022                                                
 Sep. 30 2022  -3.56       -3.55      -1.80     Beat    49.3​
 Jun. 30 2022  -3.72       -3.74      -5.52     Missed  -47.6
 Mar. 31 2022  -3.83       -4.12      -4.32     Missed  -4.9
 This summary was machine generated May 10 at 20:37 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)